Antibody-Drug Conjugates Archives - DelveInsight

Antibody-Drug Conjugates

Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future
Intellia’s Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly’s Diabetes Bloc...

A New Dawn for CRISPR, Intellia Edits Cells Inside the BodyIntellia Therapeutics, along with its partner Regeneron Pharmaceuticals, recently announced its successful attempt in editing the cel...


Johnson & Johnson
4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent Bio...

Gene therapy company 4D Molecular Therapeutics raises USD 90 Million to collaborate with AstraZeneca and Roche for moving gene therapies into clinical testing4D Molecular Therapeutics has uprais...


Default Blog Image
Sutro nets $85.4M; HiFiBiO pens Takeda R&D collaboration

Sutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which i...


The next generation of ‘weaponized antibody’ therapies

Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam. The next generation of these ‘weaponized antibody’ therapies, called ...


DelveInsight’s Oncology based Reports, 2015

DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to...


Default Blog Image
Antibody-Drug Conjugate and Big Pharmaceutical Companies

Antibody Drug Conjugate and Big Pharmaceutical Companies BoomAntibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments ...


Default Blog Image
Next Generation Antibody-Drug Conjugate Therapeutics and Market Analysis

Antibody-Drug Conjugates-A Big Boom!Therapeutics developed to create innovative medicines based on the use of new and improved antibodies is the next generation cure for the treatment of variou...


Default Blog Image
Antibody-Drug Conjugates Market Outlook, 2015 Report

264 Antibody-Drug Conjugates in Pipeline!!!!Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billion...


Default Blog Image
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy

Antibody–drug conjugates (ADCs), a new weapon of 21st Century for fighting CancerTraditional cancer chemotherapy was having harsh side effects and also leads to systemic toxicity. The approach w...


Editor's Pick
Top Drugs To Watch in HIV (2025)

Human Immunodeficiency Virus or HIV is a species of Lentivirus (genus of retrovirus) th...

An in-depth Assessment of the Top Drugs Launched by Leading Global Companies ...

Progress is driven by innovation. When it comes to developing novel medications and the...

Changing Dynamics of HIV-1 Treatment Market

The HIV-1 treatment market for naïve and experienced patients is evolving consistently....

Which Countries Top the Chart in Global Pharmaceutical Market?

The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.